Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

Benzinga Newsdesk www.benzinga.com Positive 58.7%

Neg 0% Neu 0% Pos 58.7%

Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.